Tectonic Therapeutic, Inc. (TECX) NASDAQ
29.88
-0.95(-3.08%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
29.88
-0.95(-3.08%)
Currency In USD
Address
490 Arsenal Way
Watertown, MA 02472
United States of America (the)
Phone
N/A
Website
Sector
Healthcare
Industry
Biotechnology
Employees
51
First IPO Date
June 21, 2018
| Name | Title | Pay | Year Born |
| Alise S. Reicin | President, Chief Executive Officer, Secretary & Director | 1.01M | 1961 |
| Timothy A. Springer | Co-Founder & Independent Director | 24,000 | 1949 |
| Daniel Lochner | Chief Financial Officer | 625,975 | 1982 |
| Marcella K. Ruddy | Chief Medical Officer | 700,858 | 1963 |
| Marc Schwabish | Chief Business Officer | 0 | 1982 |
| Peter McNamara | Chief Scientific Officer | 0 | 1972 |
| John Diener | Senior Vice President of Antibody Engineering & Protein Sciences | 0 | N/A |
| Anthony Muslin | Chief Development Officer | 0 | N/A |
| Barry Rubenstein | Senior Vice President of People & Culture | 0 | N/A |
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.